Empagliflozin
Indication
Chronic kidney disease (NICE TA942)
NICE TA942 - Empagliflozin for treating chronic kidney disease
Green
Brand:
Nice TA:
942
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
1.1 Empagliflozin is recommended as an option for treating chronic kidney disease (CKD) in adults, only if:
it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and
- people have an estimated glomerular filtration rate of:
- 20 ml/min/1.73 m2 to less than 45 ml/min/1.73 m2 or
- 45 ml/min/1.73 m2 to 90 ml/min/1.73 m2 and either
- a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more, or
- type 2 diabetes.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: